China's Biotech Champion Goes Global — H1 Profit Surges 627%, BRUKINSA Franchise Hits $4.5B Run-Rate — Quick Take
The daily financial summary flagged a major structural theme: global pharmaceutical giants are increasingly turning to Chinese biotech firms to tap innovation pipelines, with cross-border out-licensing by Chinese biotechs hitting $60 billion in Q1 2026 alone — a 73% jump YoY. BeOne Medicines (formerly BeiGene) is the poster child of this convergence. It appeared directly in the US VolumeSurge screener on Friday (+5.6%, $348.27, $222M turnover), Healthcare was the #4 sector in today's HK VolumeSurge (6 stocks), and the company just dropped a blowout H1 2026 report: net profit surged 627% to $485M, already exceeding full-year 2025 profit. BRUKINSA global sales hit a $4.5B annual run-rate, and the FDA just granted accelerated approval to Sonrotoclax (BEQALZI) for relapsed/refractory mantle cell lymphoma. Multiple analysts raised price targets following the print — TD Cowen to $454, Morgan Stanley to $405.
| Year | Revenue | Rev Growth | Op Margin | Net Income |
|---|---|---|---|---|
| 2022 | $1.42B | +20.4% | -126.4% | -$2.00B |
| 2023 | $2.46B | +73.7% | -49.1% | -$0.88B |
| 2024 | $3.81B | +55.0% | -14.9% | -$0.64B |
| 2025 | $5.34B | +40.2% | +8.4% | $0.29B |
| TTM (Jun '26) | $6.13B | +34.4% | +15.1% | $0.66B |
2026 guidance raised to $6.7–6.8B (44.9–46.2B yuan). BRUKINSA accounts for ~74% of total revenue ($4.5B TTM). Gross margin expanded to 88.9% TTM. Free cash flow flipped positive in 2025 ($942M) and hit $1.33B TTM.
BeOne Medicines is the best pure-play on the China biotech globalization thesis — and the numbers are finally catching up to the narrative. The operating leverage inflection is real: a company that burned $2B in 2022 is now printing $1.3B in free cash flow. BRUKINSA is a genuine global blockbuster, and the Sonrotoclax approval opens a second front. But at 44x forward earnings with 74% single-product concentration, the margin for error is thin. If you believe the China biotech BD boom is structural and BRUKINSA still has a multi-year growth runway, the post-earnings pullback from A-share highs could be an entry point. If you worry about BTK competition or pipeline execution, wait for a better price. Either way, this is the Chinese biotech name to watch in H2 2026.
Disclaimer: AI-generated quick take for informational purposes only. Not investment advice. Data from public filings, company reports, and financial data providers. BeOne Medicines trades as ONC (NASDAQ), 06160.HK (HKEX), and 688235.SS (Shanghai STAR).